Skip to main content

Table 3 Statistical comparison between pre-treatment and post-treatment parameters in glycemic improved patients

From: Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

  Pre-treatment (no = 32) Post-treatment (no = 32) P value
Hemoglobin (g/dL)a 13.07 ± 1.05 12.57 ± 1.23 0.002
Leukocytes (× 103/μL cells)a 6.53 ± 1.91 6.58 ± 2.03 0.876
Platelets (× 103/μL cells)a 206.56 ± 53.82 217.31 ± 47.82 0.130
Albumin (g/dL)a 4.30 ± 0.40 4.31 ± 0.37 0.501
Bilirubin, total (mg/dL)a 0.78 ± 0.22 0.67 ± 0.19 0.009
INRa 1.41 ± 1.75 1.07 ± 0.09 0.290
AST (IU/L)a 51.59 ± 28.20 24.53 ± 8.27 0.001
ALT (IU/L)a 64.13 ± 35.90 24.22 ± 7.98 0.001
Creatinine (mg/dL)a 0.87 ± 0.15 0.88 ± 0.15 0.525
HbA1c (%)a 7.91 ± 0.69 6.50 ± 0.72 0.001
AFP (ng/mL)a 7.41 ± 6.24 6.56 ± 5.94 0.032
FIB-4b scorea 1.75 ± 0.76 1.17 ± 0.44 0.001
  1. aMean ± SD. Glycemic improved group: ≥ 1% reduction of baseline HbA1c levels at SVR. Non-glycemic improved group: < 1% reduction of baseline HbA1c levels at SVR
  2. AFP Alpha-fetoprotein, ALT Alanine transaminase, AST Aspartate transaminase, bFIB-4 score = [age 3AST]/[platelets 3 ALT1/2], INR international normalized ratio, HbA1c glycated hemoglobin